Importer of Controlled Substances Application: Purisys, LLC, 23049-23050 [2024-07035]
Download as PDF
<![CDATA[
23049
Federal Register / Vol. 89, No. 65 / Wednesday, April 3, 2024 / Notices
Controlled substance
Drug code
lotter on DSK11XQN23PROD with NOTICES1
Nabilone .................................................................................................................................................................................
1-Phenylcyclohexylamine ......................................................................................................................................................
Phencyclidine .........................................................................................................................................................................
ANPP (4-Anilino-N-phenethyl-4-piperidine) ...........................................................................................................................
Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide) .......................................................................................................
Phenylacetone .......................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ......................................................................................................................................
Alphaprodine ..........................................................................................................................................................................
Anileridine ..............................................................................................................................................................................
Coca Leaves ..........................................................................................................................................................................
Cocaine ..................................................................................................................................................................................
Etorphine HCl ........................................................................................................................................................................
Dihydrocodeine ......................................................................................................................................................................
Diphenoxylate ........................................................................................................................................................................
Ecgonine ................................................................................................................................................................................
Ethylmorphine ........................................................................................................................................................................
Levomethorphan ....................................................................................................................................................................
Levorphanol ...........................................................................................................................................................................
Isomethadone ........................................................................................................................................................................
Meperidine .............................................................................................................................................................................
Meperidine intermediate-A ....................................................................................................................................................
Meperidine intermediate-B ....................................................................................................................................................
Meperidine intermediate-C ....................................................................................................................................................
Metazocine ............................................................................................................................................................................
Oliceridine (N-[(3-methoxythiophen-2yl)methyl] ({2-[9r)-9-(pyridin-2-yl)-6-oxaspiro[4.5] decan-9-yl] ethyl {time})amine fumarate).
Metopon .................................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ....................................................................................................................
Dihydroetorphine ...................................................................................................................................................................
Opium tincture .......................................................................................................................................................................
Opium, powdered ..................................................................................................................................................................
Opium, granulated .................................................................................................................................................................
Noroxymorphone ...................................................................................................................................................................
Phenazocine ..........................................................................................................................................................................
Thiafentanil ............................................................................................................................................................................
Piminodine .............................................................................................................................................................................
Racemethorphan ...................................................................................................................................................................
Racemorphan ........................................................................................................................................................................
Alfentanil ................................................................................................................................................................................
Remifentanil ...........................................................................................................................................................................
Sufentanil ...............................................................................................................................................................................
Carfentanil .............................................................................................................................................................................
Tapentadol .............................................................................................................................................................................
Bezitramide ............................................................................................................................................................................
Moramide-intermediate ..........................................................................................................................................................
The company plans to import small
quantities of the listed controlled
substances to support research activities
funded by the National Institute on Drug
Abuse. No other activities for these drug
codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07037 Filed 4–2–24; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
18:18 Apr 02, 2024
Jkt 262001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1339]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Purisys, LLC has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
DATES:
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
7379
7460
7471
8333
8366
8501
8603
9010
9020
9040
9041
9059
9120
9170
9180
9190
9210
9220
9226
9230
9232
9233
9234
9240
9245
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
9260
9273
9334
9630
9639
9640
9668
9715
9729
9730
9732
9733
9737
9739
9740
9743
9780
9800
9802
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
on or before May 3, 2024. Such persons
may also file a written request for a
hearing on the application on or before
May 3, 2024.
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
ADDRESSES:
Importer of Controlled Substances
Application: Purisys, LLC
Schedule
E:\FR\FM\03APN1.SGM
03APN1
23050
Federal Register / Vol. 89, No. 65 / Wednesday, April 3, 2024 / Notices
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on February 8, 2024,
Purisys, LLC, 1550 Olympic Drive,
Athens, Georgia 30601–1602, applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
lotter on DSK11XQN23PROD with NOTICES1
Marihuana Extract .........
Marihuana ......................
Tetrahydrocannabinols ..
Nabilone ........................
Phenylacetone ...............
Ecgonine ........................
Levorphanol ...................
Thebaine ........................
Opium, raw ....................
Opium, powdered ..........
Opium, granulated .........
Noroxymorphone ...........
Poppy Straw Concentrate.
Tapentadol .....................
Drug
code
Schedule
7350
7360
7370
7379
8501
9180
9220
9333
9600
9639
9640
9668
9670
I
I
I
II
II
II
II
II
II
II
II
II
II
9780
II
The company plans to import Opium,
Raw (9600), Opium, Powered (9639) and
Opium, Granulated (9640) to
manufacture an Active Pharmaceutical
Ingredient (API) only for distribution to
its customers. The company plans to
import Phenylacetone (8501) and Poppy
Straw Concentrate (9670), to bulk
manufacture other Controlled
substances for distribution to its
customers. The company plans to
import impurities of buprenorphine that
have been determined by DEA to be
captured under Thebaine (9333). In
reference to Marihuana Extract (7350),
Marihuana (7360) and
Tetrahydrocannabinols (7370) the
company plans to import as synthetic.
No other activity for these drug codes
are authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
VerDate Sep<11>2014
18:18 Apr 02, 2024
Jkt 262001
approved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07035 Filed 4–2–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
[OMB Number 1110–0073]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Crime Data
Explorer (CDE) Feedback
Federal Bureau of
Investigation, Department of Justice.
ACTION: 30-Day notice.
AGENCY:
The Federal Bureau of
Investigation (FBI), Department of
Justice (DOJ), will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection was previously
published in the Federal Register on
February 20, 2024, allowing a 60-day
comment period.
DATES: Comments are encouraged and
will be accepted for 30 days until May
3, 2024.
FOR FURTHER INFORMATION CONTACT: If
you have comments especially on the
estimated public burden or associated
response time, suggestions, or need a
copy of the proposed information
collection instrument with instructions
or additional information, please
contact: Edward L. Abraham, Crime and
Law Enforcement Statistics Unit Chief,
FBI, CJIS Division, Module D–1, 1000
Custer Hollow Road, Clarksburg, West
Virginia 26306; elabraham@fbi.gov,
304–625–4830.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
SUMMARY:
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
—Enhance the quality, utility, and
clarity of the information to be
collected; and/or
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Written comments and
recommendations for this information
collection should be submitted within
30 days of the publication of this notice
on the following website
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
30-day Review—Open for Public
Comments’’ or by using the search
function and entering either the title of
the information collection or the OMB
Control Number 1110–0073. This
information collection request may be
viewed at www.reginfo.gov. Follow the
instructions to view Department of
Justice, information collections
currently under review by OMB.
DOJ seeks PRA authorization for this
information collection for three (3)
years. OMB authorization for an ICR
cannot be for more than three (3) years
without renewal. The DOJ notes that
information collection requirements
submitted to the OMB for existing ICRs
receive a month-to-month extension
while they undergo review.
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a previously approved
collection.
2. Title of the Form/Collection: Crime
Data Explorer Feedback Survey.
3. Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: There is no form number for
this collection. The applicable
component within DOJ is the Criminal
Justice Information Services (CJIS)
Division, FBI.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Law enforcement, academia,
and the general public.
Abstract: This survey is needed to
collect feedback on the functionality of
the CDE in order to make improvements
to the application.
5. Obligation to Respond: Voluntary.
6. Total Estimated Number of
Respondents: 200 respondents.
7. Estimated Time per Respondent: 2
minutes.
E:\FR\FM\03APN1.SGM
03APN1
]]>Agencies
[Federal Register Volume 89, Number 65 (Wednesday, April 3, 2024)]
[Notices]
[Pages 23049-23050]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07035]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1339]
Importer of Controlled Substances Application: Purisys, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Purisys, LLC has applied to be registered as an importer of
basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
May 3, 2024. Such persons may also file a written request for a hearing
on the application on or before May 3, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no
[[Page 23050]]
need to resubmit the same comment. All requests for a hearing must be
sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/
DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests
for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on February 8, 2024, Purisys, LLC, 1550 Olympic Drive,
Athens, Georgia 30601-1602, applied to be registered as an importer of
the following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana Extract...................... 7350 I
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
Nabilone............................... 7379 II
Phenylacetone.......................... 8501 II
Ecgonine............................... 9180 II
Levorphanol............................ 9220 II
Thebaine............................... 9333 II
Opium, raw............................. 9600 II
Opium, powdered........................ 9639 II
Opium, granulated...................... 9640 II
Noroxymorphone......................... 9668 II
Poppy Straw Concentrate................ 9670 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to import Opium, Raw (9600), Opium, Powered
(9639) and Opium, Granulated (9640) to manufacture an Active
Pharmaceutical Ingredient (API) only for distribution to its customers.
The company plans to import Phenylacetone (8501) and Poppy Straw
Concentrate (9670), to bulk manufacture other Controlled substances for
distribution to its customers. The company plans to import impurities
of buprenorphine that have been determined by DEA to be captured under
Thebaine (9333). In reference to Marihuana Extract (7350), Marihuana
(7360) and Tetrahydrocannabinols (7370) the company plans to import as
synthetic. No other activity for these drug codes are authorized for
this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-07035 Filed 4-2-24; 8:45 am]
BILLING CODE P
